The Heart Attack Monitoring machine

The new device has been developed by the Dutch company Philips the instrument is called the Minicare I-20.

A new, portable device can assess patients for the risk of developing a heart attack by screening a single drop of blood. The test is also five times faster than comparable diagnostic devices.

The device works by assessing levels of cardiac troponin I (cTnI). This is a protein released by heart muscle into the blood following a heart attack. Detection of this specific protein informs the healthcare professional of the patient risk and allows appropriate treatment to be administered.
Troponin is a complex of three regulatory proteins (troponin C, troponin I, and troponin T), and they are necessary for muscle contraction in both skeletal muscle and cardiac muscle. Subtypes of troponin (cardiac I) are specific indicators of damage to the heart muscle (myocardium).
Assessing the levels of troponin I in the blood is important to distinguish between patients who complain of chest pains. The test can differentiate between patients up who have unstable angina and those who have myocardial infarction (heart attack.) This allows for the appropriate treatment to be delivered promptly.
Each test requires the use of single test cartridge. Into this a drop of blood for the patient is placed. The blood is screened by the instrument for multiple target molecules at low concentrations. The results of the immunoassay are assessed through special software.
The device is not only portable; it also produces a relatively rapid result. Most instruments running similar tests take around one hour to produce a result. The Philips device provides the result within 10 minutes.

The device has begun to be sold to hospitals in northern Europe. U.S, approval has yet to be sought. The next application for the instrument will be with neuropsychiatric patients. Here Philips plans to worn with Janssen Pharmaceutica N.V. The device has created a buzz on Twitter within the medical community, and it has received a generally positive reception.

Comments

The New Blood Group 'INRA'

Usually there are 4 or 5 blood groups to be known namely A,B,O,AB and rarely Bombay or HH blood group. The Bombay blood group are named after its discovery in the city Bombay (now called Mumbai city)discover by the Dr. Y.M. Bhende in 1952 and this is the first time India become a parent of the new and rarest type of blood group. It is obvious,Bomby blood group is the first blood group found in India but not the least "because discovery never stops" This saying fix here perfectly,A person with new & rare blood group is found in Lok Samparn Raktdan laboratory, Surat, Gujarat. The person’s blood group doesn’t match with any other A, B, O, AB and also Bombay Blood Group or also called as HH Blood Group. The new blood group is named as INRA; the first 2 letters represent India (IN) & the next two name of the person (RA). INRA blood group is identified for the first time when the person visited for donating blood in Blood Camp. The blood sample was prev

Autophagy: A Nobel Prize Topic

Introduction The word autophagy is derived from Greek words “auto” meaning self and “phagy” meaning eating. Autophagy is a normal physiological process in the body that deals with destruction of cells in the body. It maintains homeostasis or normal functioning by protein degradation and turnover of the destroyed cell organelles for new cell formation. During cellular stress the process of Autophagy is upscaled and increased. Cellular stress is caused when there is deprivation of nutrients and/or growth factors. Thus Autophagy may provide an alternate source of intracellular building blocks and substrates that may generate energy to enable continuous cell survival. History Autophagy has been known for over 50 years but its fundamental importance in physiology and medicine was only recognized after Yoshinori Ohsumi's paradigm-shifting research in the 1990's. For his discoveries, he is awarded this year's Nobel Prize in physiology or medicine.

Artificial Cancer-Killing Virus

It is the genome of an oncolytic virus, it is 34,000 base pairs long, and it is 100% artificial. It’s important because it not only has immediate application in studies of canine cancer, it also promises to inform the development of human therapies. In these human therapies, artificial viruses could be customized to such an extent, that they could qualify as personalized anticancer therapeutics. It is not the first time that oncolytic viruses has engineered but earlier virus like Herpes simplex and Oncorine(H101) are also being used. The virus in question in sCAV2, a conditionally replicative adenovirus (CRAd) that can target and kill tumor cells while sparing healthy cells. It was synthesized by scientists affiliated with Gen9, who worked in concert with scientists representing Autodesk and Auburn University. At Auburn, scientists led by Bruce Smith, V.M.D., Ph.D., intend to use the synthetic virus to evaluate therapeutic treatments in dogs with osteosarcoma, a

Recent In Life Sciences

Search This Blog